复方斑蝥胶囊联合XELOX化疗方案对胃癌术后患者的临床疗效

目的探讨复方斑蝥胶囊联合XELOX化疗方案(奥沙利铂+卡培他滨)对胃癌术后患者的临床疗效。方法 85例患者随机分为对照组(41例)和观察组(44例),对照组给予XELOX化疗方案,观察组在对照组基础上加用复方斑蝥胶囊,疗程21 d。然后,检测血清肿瘤标志物(CA125、CEA、CA199)、免疫功能指标(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)、不良反应发生率变化。结果治疗后,2组血清肿瘤标志物显著降低(P<0.05),以观察组更明显(P<0.05);CD3^+、CD4^+、CD4^+/CD8^+显著降低(P<0.05),以对照组更明显(P<0.05);CD8^+无显著差异(P>0.05)。观察组不良反应发生率显著低于对照组(P<0.05)。结论复方斑蝥胶囊联合XELOX化疗方案可保护胃癌术后患者机体免疫功能,提高化疗耐受性和生活质量。

Clinical effects of Compound Banmao Capsules combined with XELOX chemotherapy regimen on postoperative patients with gastric cancer

AIM To explore the clinical effects of Compound Banmao Capsules combined with XELOX chemotherapy regimen(oxaliplatin+capecitabine) on postoperative patients with gastric cancer. METHODS Eighty-five patients were randomly divided into control group(41 cases) for 21-day intervention of XELOX chemotherapy regimen, and observation group(44 cases) for 21-day intervention of Compound Banmao Capsules and XELOX chemotherapy. Subsequently, the changes in serum tumor markers(CA125, CEA, CA199), immune function indices(CD3^+, CD4^+, CD8^+, CD4^+/CD8^+) and occurrence rate of adverse reactions were detected. RESULTS After the treatment, the two groups demonstrated significantly decreased serum tumor markers(P<0.05), especially for the observation group(P<0.05);markedly reduced CD3^+, CD4^+ and CD4^+/CD8^+(P<0.05), especially for the control group(P<0.05);no obvious difference in CD8^+ was found(P>0.05). The occurrence rate of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). CONCLUSION For the postoperative patients with gastric cancer, Compound Banmao Capsules combined with XELOX chemotherapy regimen can protect body immune functions, and improve chemotherapy tolerance and life quality.